Navigation path


European cohort coordinating network on HIV drug resistance
EC contribution
: € 1.499.336
: 48 months
Starting date
: 01/03/2006
Funding scheme
: Coordinated Action
: HIV; drug-resistance; surveillance; transmission; Europe; prevention
Contract/Grant agreement number
: LSHP-CT-2006-518211
Project web-site


This coordination action will be the creation and maintenance of a pan-European cohort (including Central- and Eastern European countries) by a network of virological reference centres in over 30 European countries. This network will study the appearance, spread and clinical consequences of HIV resistance under joint standards and linked to a common shared self sustainable database.

In addition to coordinating the cohort on HIV resistance, active exchange of good practices and standards is sought with the other European HIV/Aids cohorts studying morbidity and mortality of HIV/Aids both in adults and children, mother-to-child transmission, through strategic meetings with coordinators of PENTA, ECS, CASCADE, EuroSIDA, the European Commission, EU Centre of Disease Control (ECDC) and the WHO.

By the actions proposed in this coordination action, a major contribution is being made to (i) decreasing the fragmentation of HIV resistance surveillance and research in Central- and Eastern Europe, (ii) increasing the level of virological expertise and skills in HIV resistance in this region and (iii) the desired exchange of good practices between the HIV/AIDS cohorts in Europe and the WHO.

This increased coordination made possible by EuropeHIVResistance will lead to new coordinated data and knowledge on transmission, prevalence and factors facilitating the emergence and spread of drug resistant HIV in Europe, providing the pharmaceutical industry, scientific community and public health authorities with valuable new input for the development of new drugs, new treatment recommendations, intervention programmes and prophylactic guidelines necessary to effectively confront the global emergency caused by HIV.

[+] Read More